Search Site

Teri N. Kreisl, MD

  • Assistant Professor of Neurology at CUMC
Teri N. Kreisl, MD

Dr. Teri N. Kreisl earned her medical degree from Weill Medical College of Cornell University. She was Chief Resident of her neurology program at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, then completed fellowship subspecialty training in neuro-oncology at Memorial Sloan-Kettering Cancer Center.

Subsequently, Dr. Kreisl joined the Neuro-Oncology Branch (NOB) of the Center for Cancer Research at the National Cancer Institute where she was a Tenure Track Clinical Investigator with a research focus on molecular imaging in brain tumors. Dr. Kreisl also served as Fellowship Director and Medical Director for the NOB.

She has experience as Principal Investigator for numerous phase I and II clinical trials for the treatment of primary brain tumors, and will continue similar research efforts with the Division of Neuro-oncology at Columbia University.

Dr. Teri N. Kreisl earned her medical degree from Weill Medical College of Cornell University. She was Chief Resident of her neurology program at New York Presbyterian Hospital - Weill Cornell Medical Center, then completed fellowship subspecialty training in neuro-oncology at Memorial Sloan Kettering Cancer Center. 

Subsequently, Dr. Kreisl joined the Neuro-Oncology Branch (NOB) of the Center for Cancer Research at the National Cancer Institute where she was a Tenure Track Clinical Investigator with a research focus on molecular imaging in brain tumors. 

Dr. Kreisl also served as Fellowship Director and Medical Director for the NOB.  She has experience as Principal Investigator for numerous phase I and II clinical trials for the treatment of primary brain tumors, and will continue similar research efforts with the Division of Neuro-oncology at Columbia University.

Departmental Appointments

  • Department of Neurology
    Division of Neuro-oncology

Education & Training

  • MD, Weill Cornell Medical College
  • Internship: NewYork-Presbyterian Hospital/Weill Cornell Medical Center
  • Residency: NewYork-Presbyterian Hospital/Weill Cornell Medical Center
  • Fellowship: Memorial Sloan Kettering Cancer Center

Centers/Institutes/Programs

  • Herbert Irving Comprehensive Cancer Center

NIH Grants

  • METIS: PIVOTAL, OPEN-LABEL, RANDOMIZED STUDY OF RADIOSURGERY WITH OR WITHOUT TUMOR TREATING FIELDS (TTFIELDS) FOR 1-10 BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER (NSCLC). (P&S Industry Clinical Trial)

    Mar 24 2017 - Mar 24 2022

    CYTOCHROME C OXIDASE: BIOMARKER IN NEWLY DIAG (Federal Gov)

    Sep 30 2016 - Jun 30 2020

Publications

ORIGINAL, PEER REVIEWED ARTICLES
Selesnick SH, Nguyen TD, Gutin PH, Lavyne MH. Posterior petrous face meningiomas. Otolaryngol Head Neck Surg. 2001 Apr;124(4):408-13.

Lorenzl S, Albers DS, Relkin N, Nguyen T, Hilgenberg SL, Chirichigno J, Cudkowicz ME, Beal MF. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem Int. 2003 Aug;43(3):191-6.

Nguyen TD, Abrey LE. Intracranial hemorrhage in patients treated with bevacizumab and low-molecular weight heparin. Clin Adv Hematol Oncol. 2007 May;5(5):375-6; discussion 377-9.

Kreisl TN, Toothaker T, Karimi S, DeAngelis LM. Ischemic stroke in patients with primary brain tumors. Neurology. 2008 Jun 10;70(24):2314-20.

Kreisl TN, Panageas KS, Elkin EB, Deangelis LM, Abrey LE. Treatment patterns and prognosis in patients with human immunodeficiency virus and primary central system lymphoma. Leuk Lymphoma. 2008 Sep;49(9):1710-6.

Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009 Feb 10;27(5):740-5.

Kreisl TN, Lassman AB, Mischel PS, Rosen N, Scher HI, Teruya-Feldstein J, Shaffer D, Lis E, Abrey LE. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol. 2009 Mar;92(1):99-105.

Kreisl TN, Kim L, Moore K, Duic P, Kotliarova S, Walling J, Musib L, Thornton D, Albert PS, Fine HA. A phase I trial of enzastaurin in patients with recurrent gliomas. Clin Cancer Res. 2009 May 15;15(10):3617-23.

Kreisl TN, Kotliarova S, Butman JA, Albert PS, Kim L, Musib L, Thornton D, Fine HA. A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro Oncol. 2010 Feb;12(2):181-9.

Iwamoto FM, Kreisl TN, Kim L, Duic JP, Butman JA, Albert PS, Fine HA. Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas. Cancer. 2010 Apr 1;116(7):1776-82.

Park JK, Hodges T, Arko L, Shen M, Dello Iacono D, McNabb A, Olsen Bailey N, Kreisl TN, Iwamoto FM, Sul J, Auh S, Park GE, Fine HA, Black PM. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol. 2010 Aug 20;28(24):3838-43.

Lehky TJ, Iwamoto FM, Kreisl TN, Floeter MK, Fine HA. Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome. Neurology. 2011 Jan 18;76(3):236-41.

Kreisl TN, Zhang W, Odia Y, Shih JH, Butman JA, Hammoud D, Iwamoto FM, Sul J, Fine HA. A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro Oncol. 2011 Oct;13(10):1143-50.

Fraum TJ, Kreisl TN, Sul J, Fine HA, Iwamoto FM. Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. J Neurooncol. 2011 Nov;105(2):281-9.

Kreisl TN, McNeill KA, Sul J, Iwamoto FM, Shih J, Fine HA. A phase I/II trial of vandetanib for patients with recurrent malignant glioma. Neuro Oncol. 2012 Dec;14(12):1519-26.

Kreisl TN, Smith P, Sul J, Salgado C, Iwamoto FM, Shih JH, Fine HA. Continuous daily sunitinib for recurrent glioblastoma. J Neurooncol. 2013 Jan;111(1):41-8.

Ho J, Ondos J, Ning H, Smith S, Kreisl T, Iwamoto F, Sul J, Kim L, McNeil K, Krauze A, Shankavaram U, Fine HA, Camphausen K. Chemoirradiation for glioblastoma multiforme: the National Cancer Institute experience. PLoS One. 2013;8(8):e70745.

Peer CJ, Brown JL, Martin TJ, Roth J, Spencer SD, Brassil P, McNeill KA, Kreisl TN, Fine HA, Figg WD. A novel uHPLC-MS/MS method for the quantitation of AZD7451 (AZ12607092) in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Dec 30;942-943:107-12.

REVIEWS
Nguyen T, Deangelis LM. Treatment of brain metastases. J Support Oncol. 2004 Sep-Oct;2(5):405-10; discussion 411-6.

Nguyen T, DeAngelis LM. Stroke in cancer patients. Curr Neurol Neurosci Rep. 2006 May;6(3):187-92.

Nguyen TD, Abrey LE. Brain metastases: old problem, new strategies. Hematol Oncol Clin North Am. 2007 Apr;21(2):369-88.

Nguyen TD, DeAngelis LM. Brain metastases. Neurol Clin. 2007 Nov;25(4):1173-92, x-xi.

Kreisl TN. Neurologic complications of antitumor antibody therapies. Curr Neurol Neurosci Rep. 2008 May;8(3):259-63.

Kreisl TN. Chemotherapy for malignant gliomas. Semin Radiat Oncol. 2009 Jul;19(3):150-4.

*Moustakas A, Kreisl TN. New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab. Onco Targets Ther. 2010 Jun 24;3:27-38.

ABSTRACTS
Nguyen TD, Lassman AB, Lis E, et al. A pilot study to assess the tolerability and efficacy of RAD-001 (everolimus) with gefitinib in patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol (Meeting Abstracts) 2006;24:1507-. Oral presentation.

Kreisl TN, Panageas K, Elkin E, DeAngelis L, Abrey L. Treatment patterns and prognosis in patients with human iffmunodeficiency virus (HIV) and primary central nervous system lymphoma (PCNSL). Neuro-Onc (Meeting Abstracts) 2007:48.

Kreisl TN, Kim L, Moore K, Duic P, Kotliarova S, Walling J, Musib L, Thornton D, Albert PS, Fine HA. A phase I trial of enzastaurin in patients with recurrent gliomas. Select poster presentation Society for Neuro-Oncology Annual Meeting November 2008.

Kreisl TN, Butman JA, Albert PS, Kim L, Moore K, Fine HA.  A phase II trial of vandetanib for patients with recurrent glioblastoma multiforme. Select poster presentation Society for Neuro-Oncology Annual Meeting November 2008.

Zhang W,•Kreisl TN,•Solomon J,•Fine HA,•Butman JA.  Comparison of 1D, 2D, and 3D Estimates of Enhancing Tumor Volume for Prediciting Survival in Recurrent Glioblastoma. American Society of Neuroradiology Annual Meeting May 2009.

Zhang W, Kreisl TN, Solomon J, Reynolds RC, Glen DR, Cox RW, Fine HA, Butman JA. Acute effects of bevacizumab on glioblastoma vascularity assessed with DCE-MRI and relation to patient survival. ISMRM Annual Meeting 2009.

Lehky TJ, Iwamoto F, Kreisl T, Fine HA, Floeter M. Electrophysiological findings in a patient treated with tandutinib: case report. AANEM Annual Meeting October 2009.

Kreisl TN, Butman JA, Iwamoto F, Kim L, Duic P, Albert PS, Fine HA. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent anaplastic glioma.  Society for Neuro-Oncology Annual Meeting October 2009.

McNicol K, Kreisl TN, Iwamoto F, Sul J, Fine H. A phase I/II study of vandetanib for patients with recurrent malignant gliomas.  ASCO Annual Meeting June 2010.

Moustakas A, Iwamoto FM, Kreisl TN, Sul J, Kim LJ, Butman JA, Albert PS, Fine HA. Phase II trial of enzastaurin (Enz) with bevacizumab (BV) in adults with recurrent glioblastoma (GBM). ASCO Annual Meeting June 2010.

Smith P, Kreisl TN, Iwamoto F, Sul J, Butman JA, Fine HA. A Phase II Trial of Sunitinib in the Treatment of Recurrent Glioblastoma (GBM). Society for Neuro-Oncology Annual Meeting November 2010.

*Kreisl TN, Kreisl WC, Herscovitch P, Innis R. [11C]N-Desmethyl-Loperamide as a Marker of PgP Function in Patients with Gliomas. The 9th International Symposium on Functional Neuroreceptor Mapping of the Living Brain (NRM12) August 2012.

Sul J, Odia Y, Zhang W, Shih J, Butman JA, Hammoud D, Kreisl TN, Iwamoto F, Fine HA. A phase I trial of investigational agent tandutinib in combination with bevacizumab for patients with recurrent glioblastoma. Society for Neuro-Oncology Annual Meeting 2012.

Sul J, Hilf N, Kutscher S, Schoor O, Lindner J, Reinhardt C, Kreisl TN, Iwamoto F, Fine HA, Singh H. A phase I trial of peptide-based glioma vaccine IMA950 in patients with glioblastoma: study design and preliminary results. Society for Neuro-Oncology Annual Meeting 2013.ORIGINAL, PEER REVIEWED ARTICLES
Selesnick SH, Nguyen TD, Gutin PH, Lavyne MH. Posterior petrous face meningiomas. Otolaryngol Head Neck Surg. 2001 Apr;124(4):408-13.

Lorenzl S, Albers DS, Relkin N, Nguyen T, Hilgenberg SL, Chirichigno J, Cudkowicz ME, Beal MF. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem Int. 2003 Aug;43(3):191-6.

Nguyen TD, Abrey LE. Intracranial hemorrhage in patients treated with bevacizumab and low-molecular weight heparin. Clin Adv Hematol Oncol. 2007 May;5(5):375-6; discussion 377-9.

Kreisl TN, Toothaker T, Karimi S, DeAngelis LM. Ischemic stroke in patients with primary brain tumors. Neurology. 2008 Jun 10;70(24):2314-20.

Kreisl TN, Panageas KS, Elkin EB, Deangelis LM, Abrey LE. Treatment patterns and prognosis in patients with human immunodeficiency virus and primary central system lymphoma. Leuk Lymphoma. 2008 Sep;49(9):1710-6.

Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009 Feb 10;27(5):740-5.

Kreisl TN, Lassman AB, Mischel PS, Rosen N, Scher HI, Teruya-Feldstein J, Shaffer D, Lis E, Abrey LE. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol. 2009 Mar;92(1):99-105.

Kreisl TN, Kim L, Moore K, Duic P, Kotliarova S, Walling J, Musib L, Thornton D, Albert PS, Fine HA. A phase I trial of enzastaurin in patients with recurrent gliomas. Clin Cancer Res. 2009 May 15;15(10):3617-23.

Kreisl TN, Kotliarova S, Butman JA, Albert PS, Kim L, Musib L, Thornton D, Fine HA. A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro Oncol. 2010 Feb;12(2):181-9.

Iwamoto FM, Kreisl TN, Kim L, Duic JP, Butman JA, Albert PS, Fine HA. Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas. Cancer. 2010 Apr 1;116(7):1776-82.

Park JK, Hodges T, Arko L, Shen M, Dello Iacono D, McNabb A, Olsen Bailey N, Kreisl TN, Iwamoto FM, Sul J, Auh S, Park GE, Fine HA, Black PM. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol. 2010 Aug 20;28(24):3838-43.

Lehky TJ, Iwamoto FM, Kreisl TN, Floeter MK, Fine HA. Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome. Neurology. 2011 Jan 18;76(3):236-41.

Kreisl TN, Zhang W, Odia Y, Shih JH, Butman JA, Hammoud D, Iwamoto FM, Sul J, Fine HA. A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro Oncol. 2011 Oct;13(10):1143-50.

Fraum TJ, Kreisl TN, Sul J, Fine HA, Iwamoto FM. Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. J Neurooncol. 2011 Nov;105(2):281-9.

Kreisl TN, McNeill KA, Sul J, Iwamoto FM, Shih J, Fine HA. A phase I/II trial of vandetanib for patients with recurrent malignant glioma. Neuro Oncol. 2012 Dec;14(12):1519-26.

Kreisl TN, Smith P, Sul J, Salgado C, Iwamoto FM, Shih JH, Fine HA. Continuous daily sunitinib for recurrent glioblastoma. J Neurooncol. 2013 Jan;111(1):41-8.

Ho J, Ondos J, Ning H, Smith S, Kreisl T, Iwamoto F, Sul J, Kim L, McNeil K, Krauze A, Shankavaram U, Fine HA, Camphausen K. Chemoirradiation for glioblastoma multiforme: the National Cancer Institute experience. PLoS One. 2013;8(8):e70745.

Peer CJ, Brown JL, Martin TJ, Roth J, Spencer SD, Brassil P, McNeill KA, Kreisl TN, Fine HA, Figg WD. A novel uHPLC-MS/MS method for the quantitation of AZD7451 (AZ12607092) in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Dec 30;942-943:107-12.

For a complete list of publications, please visit PubMed.gov